An Evaluation of Biotech Firms Part 3

A Comprehensive Essay

Part 3

In parts 1 and 2 of this comprehensive essay Vertex (VRTX) was the firm we used as a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. As a matter of fact, we use the histories of real firms in this essay for the sake of demonstrating the above without considering the Companies’ technologies or approved and investigational products, but instead rely only on their stocks’ past performances; no fair evaluation can be possible, which misleads investors.

We have many cases in point which demonstrate various conditions where selloffs of biotech stocks, following some disappointing news, could be superb news for savvy investors who instead of joining the sellers prefer to take advantage of the declined stocks’ prices to buy or accumulate them at bargain prices. We will start Part 3 with our picked firm Incyte as a case in point. 

Incyte

The Setback

Leave a Reply